On 9 June 2026, EU Home Affairs Commissioner Magnus Brunner launched the European Drugs Report 2026, describing the findings as alarming and calling for a comprehensive EU response covering prevention, treatment and security. The report shows cocaine is more available than ever, with seizures rising to 97,000 in 2024 despite a 20% drop in intercepted volume, and at least 7,600 overdose deaths in Europe.
Brunner stressed that drug trafficking finances money laundering, corruption, human trafficking and other serious organised crime, with criminal networks using advanced technology and exploiting social vulnerabilities. He outlined the EU's comprehensive approach, citing the new EU drugs strategy, the Action Plan against drug trafficking, and proposed rules for monitoring drug precursors. The strategy combines public health measures with law enforcement to reduce both supply and demand.
On law enforcement, Brunner highlighted the European action plan against drug trafficking presented at the end of 2025, targeting criminal networks along the entire supply chain. A key focus is port security through the European Ports Alliance, where he reported good results. He also emphasised intensifying cooperation with partner countries in Latin America, noting that drug trafficking is a global business requiring a global response. The report will feed into discussions at the European Council next week.
The speech contained concrete proposals, including the action plan and port security measures, but no new numerical targets or budget figures were announced. The policy orientation is towards stronger security and law enforcement, with a balanced emphasis on public health. The speech did not address specific stakeholder reactions or implementation timelines.
EU law enforcement agencies will see increased cooperation and resources for port security and cross-border operations. Drug trafficking networks face heightened risk of disruption along supply chains. Public health systems may benefit from integrated prevention and treatment measures, but could face administrative burdens. EU producers of drug precursors will be affected by new monitoring rules, potentially increasing compliance costs.